References
- Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy, and monitoring. Am J Hematol. 2020;95(6):691–709. doi:10.1002/ajh.25792
- Calabretta B, Perrotti D. Biology of the CML blast crisis. Blood. 2004;103(11):4010–4022. doi:10.1182/blood-2003-12-4111
- Rossari F, Minutolo F, Orciuolo E. Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy. J Hematol Oncol. 2018;11(1):84. doi:10.1186/s13045-018-0624-2
- O'Hare T, Eide CA, Deininger MW. BCR-ABL kinase domain mutations, drug resistance, and the pathway for curing chronic myeloid leukemia. Blood. 2007;110(7):2242–2249. doi:10.1182/blood-2007-03-066936
- Massaro F, Molica M, Breccia M. Ponatinib: a review of efficacy and safety. Curr Cancer Drug Targets. 2018;18(9):847–856. doi:10.2174/1568009617666171002142659
- Okabe S, Tauchi T, Tanaka Y, et al. Activity of omacetaxine mepesuccinate against ponatinib-resistant BCR-ABL-positive cells. Blood. 2013;122(17):3086–3088. doi:10.1182/blood-2013-04-494773
- Shanmuganathan N, Hughes TP. Asciminib for chronic myeloid leukaemia: next questions. Br J Haematol. 2022;199(3):322–331. doi:10.1111/bjh.18323
- Chen D, Frezza M, Schmitt S, et al. Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives. Curr Cancer Drug Targets. 2011;11(3):239–253. doi:10.2174/156800911794519752
- Santos FP, Kantarjian H, McConkey D, et al. Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase. Clin Lymphoma Myeloma Leuk. 2011;11(4):355–360. doi:10.1016/j.clml.2011.06.004
- Lu L, Kok CH, Saunders VA, et al. Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib-resistant BCR-ABL1+ cell lines. Oncotarget. 2018;9(78):34735–34747. doi:10.18632/oncotarget.26187
- Qiang W, Antelope O, Zabriskie MS, et al. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib. Leukemia. 2017;31(12):2844–2847. doi:10.1038/leu.2017.264
- Réa D, Hughes TP. Development of asciminib as a novel allosteric inhibitor of BCR-ABL1. Crit Rev Oncol Hematol. 2022;171:103580. doi:10.1016/j.critrevonc.2022.103580
- Heaney NB, Pellicano F, Zhang B, et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells, including LTC-IC-and NOD/SCID-repopulating cells. Blood. 2010;115(11):2241–2250. doi:10.1182/blood-2008-06-164582